This technology is a three-dimensional decellularized bone scaffold that replicates the tumor microenvironment for more accurate cell culture and drug screening for Ewing’s sarcoma.
Prostate cancer and Ewing's sarcoma are human diseases that are not accurately represented in an animal model. As a result, current experimental methods and models to study cancer growth and progression mainly utilize in vitro two-dimensional (2D) co-culturing of cancer specific cell lines and other cells found locally in the tumor. However, these 2D models fail to capture the true three-dimensional (3D) progression of tumors and are limited in their ability to identify therapeutic targets, leading to the failure to translate observed in vitro effects to in vivo studies. Therefore, there remains a substantial need for a 3D culture model that accurately models the tumor microenvironment and tumor phenotypes.
This technology is a 3D decellularized bone scaffold that is seeded with cancer cells to accurately model various forms of cancer and the in vivo tumor phenotype and microenvironment. The 3D scaffold can be used in a high-throughput assay with cancer cell lines, such as prostate cancer and Ewing's sarcoma, to identify therapeutic targets and drug candidates. Additionally, this scaffold can also be used with patient-derived cancer cells and mesenchymal stem cells for a personalized approach to cancer modelling and treatment. As a result, this technology offers a controllable, quantitative, and clinically-relevant approach for studying and treating cancers such as Ewing sarcoma (ES).
A prototype of this technology has been demonstrated to accurately mimic the native bone tumor microenvironment of Ewing’s sarcoma.
Gordana Vunjak-Novakovic, Ph.D.
Patent Pending (US 20160168542)
Villasante A, Marturano-Kruik A, Vunjak-Novakovic G. “Bioengineered human tumor within a bone niche” Biomaterials. 2014 Jul;35(22):5785-94. Editor’s Choice, Science Translational Medicine K. L. Spiller, How to Build a Better Bone Tumor. Sci. Transl. Med. 6, 235ec81, 2014.
IR CU14010
Licensing Contact: Beth Kauderer